BioKangtai

Zawya · Jan 19 at 11:18 PM

ZAWYA-SNG: Egypt advances local production of pneumococcal vaccine through VACSERA partnership

Zhitong · Nov 3, 2025 at 05:14 AM

BioKangtai: Quadrivalent influenza virus split vaccine (for the population aged 6-35 months) has initiated Phase I clinical trials

Zhitong · Oct 27, 2025 at 04:38 AM

BioKangtai released its performance for the first three quarters, with a net profit attributable to the parent company of 49.1577 million yuan, a decrease of 86%

Zhitong · Oct 27, 2025 at 03:09 AM

BioKangtai's net profit for the third quarter is 11.6 million yuan, and the net profit for nine months is 49.2 million yuan

Zhitong · Sep 30, 2025 at 03:12 AM

BioKangtai and AstraZeneca sign a license termination agreement

Zhitong · Sep 24, 2025 at 05:06 AM

BioKangtai: Application for marketing authorization of trivalent influenza virus split vaccine accepted